NCT07521657
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07521657
Title Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma (NF118)
Acronym NF118
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Alabama at Birmingham
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries USA

Facility Status City State Zip Country Details
Childrens of Alabama Birmingham Alabama 34294 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field